Delving into the Latest Updates on Bakuchiol derivative compound 28 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Action

modulators

Mechanism

Cell membrane structures modulators

Therapeutic Areas

Infectious Diseases

Active Indication

Pseudomonas aeruginosa infectionStaphylococcus Aureus Infections

Inactive Indication-

Originator Organization

Guangzhou Medical University

Active Organization

Guangzhou Medical University

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Infections caused by drug-resistant bacteria seriously endanger human health and global public health. Therefore, it is urgent to discover and develop novel antimicrobial agents to combat multidrug-resistant bacteria. In this study, we designed and synthesized a series of new membrane-active bakuchiol derivatives by biomimicking the structure and function of cationic antibacterial peptides. The most promising compound 28 displayed potent antibacterial activity against both Gram-positive bacteria (minimum inhibitory concentration, MIC = 1.56-3.125 μg/mL) and Gram-negative bacteria (MIC = 3.125 μg/mL), very weak hemolytic activity, and low cytotoxicity. Compound 28 had rapid bactericidal properties and avoided bacterial resistance. More importantly, compound 28 showed strong in vivo antibacterial efficacy against Staphylococcus aureus and Pseudomonas aeruginosa in murine corneal infection models. This design strategy is expected to provide an effective solution to the antibiotic crisis.

100 Deals associated with Bakuchiol derivative compound 28

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pseudomonas aeruginosa infection	Preclinical	China	Guangzhou Medical University	28 Apr 2021
Staphylococcus Aureus Infections	Preclinical	China	Guangzhou Medical University	28 Apr 2021